Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-derived claims largely align with the prescribing information for pharmacokinetics (oral and depot) with correct statements on half-lives and depot characteristics. Several claims are unsupported or only partially supported (notably age-related half-life changes and some depot-specific details). Important safety content (boxed warning and dose considerations for hepatic impairment and drug interactions) is not addressed by the claims and represents a safety omission.
Category Scores
Accurate Statements
Oral aripiprazole elimination half-life is about 75 hours (roughly 3 days).
Supported by 12.3 Pharmacokinetics (half-life ~75 hours; dehydro-aripiprazole ~94 hours)
Active metabolite dehydro-aripiprazole half-life is about 94 hours.
Supported by 12.3 Pharmacokinetics (dehydro-aripiprazole ~94 hours)
Steady-state with regular dosing is reached in roughly 1–2 weeks.
Supported by 12.3 Pharmacokinetics (steady-state within about 1–2 weeks for oral aripiprazole)
Aripiprazole half-life can vary with liver function.
Supported by 12.3 Pharmacokinetics (hepatic impairment affects exposure)
Aripiprazole half-life can vary with drug interactions.
Supported by 12.3 Pharmacokinetics (drug interactions via CYP2D6/CYP3A4)
Aripiprazole is metabolized mainly by CYP2D6 and CYP3A4.
Partially supported by 8.6 (CYP2D6 and CYP3A4 involvement; other pathways may exist)
For the long-acting injectable (depot) form, it produces a slow, extended release.
Supported by 12.3 Pharmacokinetics (depot releases slowly)
The apparent elimination is longer due to the depot.
Supported by 12.3 Pharmacokinetics (depot prolongs apparent elimination)
Unsupported Statements
Steady-state is reached after about 5 half-lives.
Label indicates steady-state by the fourth dose for depot; no 5-half-life rule stated
Aripiprazole half-life can vary with age.
Age-related variation not supported by label; 8.5 discusses elderly considerations but not half-life variability
Exact half-life numbers for the depot form are not the same as the oral form.
Label does not provide depot-specific half-life numbers
Contradictions
Important Omissions
Boxed warning for dementia-related psychosis mortality risk
Importance:
High
Dosing considerations with hepatic impairment and drug interactions
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Claims largely align with label for PK; however, critical safety content (boxed warning, hepatic impairment dosing, and drug interaction dosing considerations) is not addressed by the claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing Boxed Warning coverage and dosing guidance for hepatic impairment and drug interactions
Suggested Improvement
Incorporate boxed warning content and explicit hepatic impairment and drug interaction dosing guidance from the label; clarify depot-specific PK details separate from oral PK.